Patents by Inventor François Legay
François Legay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140243265Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: NOVARTIS AGInventors: Mara FORNARO, John XU, Yuan GAO, Rainer HILLENBRAND, Francois LEGAY, Daniela STOELLNER
-
Patent number: 8753632Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.Type: GrantFiled: November 10, 2009Date of Patent: June 17, 2014Assignee: Novartis AGInventors: Mara Fornaro, John Xu, Yuan Gao, Rainer Hillenbrand, Francois Legay, Daniela Stoellner
-
Patent number: 8329872Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.Type: GrantFiled: November 7, 2011Date of Patent: December 11, 2012Assignee: Novartis AGInventors: Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Severine Marrony, Judith Schaefer
-
Publication number: 20120115247Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.Type: ApplicationFiled: November 7, 2011Publication date: May 10, 2012Inventors: Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Séverine Marrony, Judith Schaefer
-
Publication number: 20120028896Abstract: A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins.Type: ApplicationFiled: June 3, 2011Publication date: February 2, 2012Inventors: Jacques BOLLEKENS, Salah-Dine CHIBOUT, Jacky VONDERSCHER, Francois LEGAY, Andre CORDIER, Ruben PAPOIAN, Andreas SCHERER
-
Patent number: 8076160Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.Type: GrantFiled: September 26, 2008Date of Patent: December 13, 2011Assignee: Novartis AGInventors: Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Severine Marrony, Judith Schaefer
-
Publication number: 20110218145Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.Type: ApplicationFiled: November 10, 2009Publication date: September 8, 2011Applicant: NOVARTIS AGInventors: Mara Fornaro, John Xu, Yuan Gao, Rainer Hillenbrand, Francois Legay, Daniela Stoellner
-
Publication number: 20100216254Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.Type: ApplicationFiled: September 26, 2008Publication date: August 26, 2010Inventors: Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Severine Marrony, Judith Schaefer
-
Publication number: 20090093398Abstract: A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months.Type: ApplicationFiled: November 5, 2004Publication date: April 9, 2009Inventors: Jacques Bollekens, Salah-Dine Chibout, Jacky Vonderscher, Francois Legay, Andre Cordier, Ruben Papoian, Andreas Scherer
-
Patent number: 6959124Abstract: The present invention provides an electro-optical device, characterized in that it comprises two plane optical substrates (100) each having at least one optical waveguide (110), and a nematic liquid crystal (200) inserted between them, in which the liquid crystal (200) is split into two separate active zones (210, 220) serving to control coupling/decoupling of a respective one of the TE and TM polarizations of a light signal injected into the waveguides (110).Type: GrantFiled: June 13, 2002Date of Patent: October 25, 2005Assignee: NemopticInventors: Alain Boissier, Jean-Francois Legay, Olivier Duhem, Philippe Martinot-Lagarde
-
Publication number: 20040202398Abstract: The present invention provides an electro-optical device, characterized in that it comprises two plane optical substrates (100) each having at least one optical waveguide (110), and a nematic liquid crystal (200) inserted between them, in which the liquid crystal (200) is split into two separate active zones (210, 220) serving to control coupling/decoupling of a respective one of the TE and TM polarizations of a light signal injected into the waveguides (110).Type: ApplicationFiled: December 15, 2003Publication date: October 14, 2004Inventors: Alain Boissier, Jean-Francois Legay, Olivier Duhem, Philippe Martinot-Lagarde
-
Patent number: 6187547Abstract: A new method of measuring blood levels of immunophilin-binding pharmaceuticals, e.g., cyclosporins, rapamycins, and FK506 compounds is provided, comprising the novel step of displacing the pharmaceutical from its immunophilin by using a binding competitor, thereby eliminating the need for an extraction step and enhancing the simplicity and accuracy of the assay. Assay kits comprising a binding competitor and a receptor, e.g., a monoclonal antibody, which binds to the pharmaceutical but not significantly to the binding competitor are also provided, as are new uses of immunophilin-binding compounds as binding competitors in such assays.Type: GrantFiled: August 6, 1998Date of Patent: February 13, 2001Assignee: Novartis AGInventors: François Legay, Roland Wenger
-
Patent number: 5738825Abstract: A detection cell which is used as a component of an optical biosensor comprises a transparent base plate and a sample plate on the base plate. The sample plate has a matrix of wells extending through it to each to receive a sample. The base plate includes a waveguiding film and a diffraction grating means to in couple an incident light field into the waveguiding film beneath a well to generate a diffracted light field to enable detection of a change in the effective refractive index of the waveguiding film.Type: GrantFiled: May 12, 1997Date of Patent: April 14, 1998Assignees: Balzers Aktiengesellschaft, Artificial Sensing Instruments ASI AGInventors: Helmut Rudigier, Roland Pfefferkorn, Kurt Tiefenthaler, Veronique Briquet, Alois Zetting, Peter Marbach, Francois Legay, Peter End